063 L’interféron α dans le traitement des lésions mélaniques de la conjonctive

Purpose Melanocytic conjunctival lesions can be treated by controlled observation, surgery, irradiation, heat application, cryotherapy or topical chemotherapy. This non-comparative prospective case series reports on the first topical Interferon a-2b therapy for the treatment of melanocytic conjunctival lesions. Patients and Methods 9 patients with histologically proven acquired melanosis with dysplasia and/or conjunctival melanoma have been treated with recombinant IFN a-2b (Intron A ® , essex pharma). The agent was diluted under sterile conditions to 1 Mio IU/ml Intron A ® and packed in single dose units (EDO) by the pharmacy. It was stored in the refrigerator and applied 5 × 1 drop/day topically by the patient for 6 weeks. The patients were seen after 2 weeks and after the end of the treatment. Results 9 lesions of 9 patients showed complete or almost complete regression and lost pigmentation. 4 patients were treated twice after the first therapy because of incomplete regression. Only one of those patients needed a third cycle of therapy to show stabile regression. The follow-up is 14 months (median). No local or systemic side effects were encountered. The pre- and post-therapy clinical pictures will be presented. Discussion Our observations suggest that topically applied Interferon a-2b might be an effective agent for the therapy of melanocytic conjunctival tumours with so far no adverse side effects. It might be an alternative to other more toxic chemotherapeutical agents. Conclusion A prospective multicenter study will help to finally evaluate the potential of topical Interferon therapy for melanocytic conjunctival tumours, in particular PAM with atypia and minimal invasive conjunctival melanoma.